Kukje Pharma Co Ltd (KO:002720) — Market Cap & Net Worth
Market Cap & Net Worth: Kukje Pharma Co Ltd (002720)
Kukje Pharma Co Ltd (KO:002720) has a market capitalization of $58.92 Million (₩86.95 Billion) as of October 11, 2026. Listed on the KO stock exchange, this Korea-based company holds position #21306 globally and #1267 in its home market, demonstrating a 31.59% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Kukje Pharma Co Ltd's stock price ₩4270.00 by its total outstanding shares 20362502 (20.36 Million).
Kukje Pharma Co Ltd Market Cap History: 2015 to 2026
Kukje Pharma Co Ltd's market capitalization history from 2015 to 2026. Data shows growth from $40.21 Million to $58.92 Million (1.76% CAGR). Check current stock price of Kukje Pharma Co Ltd for real-time trading data and today's change.
Kukje Pharma Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Kukje Pharma Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Also see Kukje Pharma Co Ltd (002720) cash conversion ratio for how efficiently the company converts equity into cash flow.
Latest Price to Sales (P/S) Ratio
0.00x
Kukje Pharma Co Ltd's market cap is 0.00 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.01x
Kukje Pharma Co Ltd's market cap is 0.01 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $40.21 Million | $117.64 Billion | -$5.94 Billion | 0.00x | N/A |
| 2016 | $51.27 Million | $120.68 Billion | $773.06 Million | 0.00x | 0.07x |
| 2017 | $61.14 Million | $123.31 Billion | $1.09 Billion | 0.00x | 0.06x |
| 2018 | $50.90 Million | $107.68 Billion | $2.19 Billion | 0.00x | 0.02x |
| 2019 | $55.19 Million | $111.12 Billion | -$4.76 Billion | 0.00x | N/A |
| 2020 | $120.40 Million | $130.39 Billion | $2.20 Billion | 0.00x | 0.05x |
| 2021 | $76.85 Million | $119.75 Billion | -$1.56 Billion | 0.00x | N/A |
| 2022 | $72.28 Million | $126.58 Billion | $3.56 Billion | 0.00x | 0.02x |
| 2023 | $81.69 Million | $135.37 Billion | -$8.42 Billion | 0.00x | N/A |
| 2024 | $69.82 Million | $156.46 Billion | $5.21 Billion | 0.00x | 0.01x |
Competitor Companies of 002720 by Market Capitalization
Companies near Kukje Pharma Co Ltd in the global market cap rankings as of October 11, 2026. See net asset quality index of Kukje Pharma Co Ltd to understand what proportion of total assets are financed by equity.
Key companies related to Kukje Pharma Co Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #524 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #585 globally with a market cap of $46.39 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #628 globally with a market cap of $43.73 Billion USD ( CN¥298.86 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #630 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #524 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #585 | GALDERMA GROUP AG | NYSE:GALDY | $46.39 Billion | $39.79 |
| #628 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $43.73 Billion | CN¥46.85 |
| #630 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €16.30 |
Kukje Pharma Co Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Kukje Pharma Co Ltd's market cap moved from $40.21 Million to $ 58.92 Million, with a yearly change of 1.76%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩58.92 Million | -0.70% |
| 2025 | ₩59.34 Million | -15.02% |
| 2024 | ₩69.82 Million | -14.53% |
| 2023 | ₩81.69 Million | +13.02% |
| 2022 | ₩72.28 Million | -5.94% |
| 2021 | ₩76.85 Million | -36.17% |
| 2020 | ₩120.40 Million | +118.14% |
| 2019 | ₩55.19 Million | +8.43% |
| 2018 | ₩50.90 Million | -16.75% |
| 2017 | ₩61.14 Million | +19.25% |
| 2016 | ₩51.27 Million | +27.52% |
| 2015 | ₩40.21 Million | -- |
End of Day Market Cap According to Different Sources
On Oct 10th, 2026 the market cap of Kukje Pharma Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $58.92 Million USD |
| MoneyControl | $58.92 Million USD |
| MarketWatch | $58.92 Million USD |
| marketcap.company | $58.92 Million USD |
| Reuters | $58.92 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Kukje Pharma Co Ltd
Kukje Pharma Co., Ltd. engages in manufacturing, importing, exporting, selling, and distributing pharmaceutical products. The company offers pharmaceutical products, including ETC and OTC products, raw materials, intermediates, and side chain products, as well as cosmetics and health care products. Its products include cephalosporins, quinolones, tetracycline, aminoglycosides, macrolides, other a… Read more